Fibromyalgia Market Snapshot: Forest Delays Savella Launch

Forest is delaying the launch of its recently approved fibromyalgia drug Savella (milnacipran) until at least May, when FDA is expected to okay a tablet-color change. Analysts do not anticipate the move will impact the drug's long-term sales when it joins Pfizer's Lyrica and Lilly's Cymbalta on the market

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet